Skipping Toward Resistance: The Gradual Adaptation of Cancer Cells

Instead of an on-off toggle switch, cancer cells adapt through a series of distinct states of increasing drug resistance.

Laura Tran, PhD
| 4 min read
Image of a cancer cell skipping across the water.

Researchers likened cancer cells to a stone skipping across water, with each skip representing a stage where the water becomes more "agitated," symbolizing the cells' growing resistance to therapy.

Marzia Munafò

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Malignant entities such as pathogens and cancer cells must improvise, adapt, and overcome efforts that thwart their growth and proliferation. One of these defenses is developing drug resistance. Inspired by findings that bacteria became increasingly resistant to higher concentrations of antibiotics, systems biologist Itai Yanai at New York University sought to explore whether cancer cells showed a similar adaptive process.1

“If we’re fighting cancer with drugs, it’s crucial to know your enemy. It’s not just transitioning to one resistant state, but it could keep transitioning,” said Yanai. “It’s like a moving target.”

Headshot image of Itai Yanai, a systems biologist at New York University, who studies evolutionary and developmental biology of cancer gene programs. He smiles at the camera and wears a blue button-up shirt.
Itai Yanai, a systems biologist at New York University, who studies evolutionary and developmental biology of cancer gene programs.
Tony Rinaldo

In a new study, Yanai and his team assessed progressive changes in cancer cells when dosed with increasing drug concentrations over a year. They observed that the cells developed resistance in a stepwise manner, with each level marked by distinct characteristics—they described this pattern as a resistance continuum. Their findings, published in Nature, suggest that the emergence of distinct adaptive states could be leveraged to develop more targeted drug combinations tailored to specific cellular states.2

First, Gustavo França, a postdoctoral researcher in Yanai’s team and coauthor of the study, treated ovarian cancer cell lines with a ramp of the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, olaparib. Drug-naïve cells initially received a relatively low one micromolar dose. After about one month, when the cells adapted and reached confluency, França seeded them onto a new plate with a higher dose, eventually reaching 320 micromolar of the drug. Over 12 months, França generated 10 different adapted cell populations.

Using single-cell RNA sequencing (scRNA-seq), the team compared the 10 cell populations and defined five major transcriptional states, S1 to S5. Along the resistance continuum, the S1 state included less drug-resistant cells while the S5 state indicated highly drug-resistant cells.

“The notion is that it’s like a skipping stone. When you skip a stone on the water, every skip is in a different state. By the end, the cancer [cell] is very resistant,” said Yanai. Each state’s underlying gene expression was distinct. For instance, the expression of lineage-defining transcription factors and epithelial markers decreased along the continuum, which indicated dedifferentiation. The researchers also observed morphologic changes as cells underwent an epithelial to mesenchymal transition (EMT).

Headshot image of Gustavo França, a postdoctoral researcher in Yanai’s group. He is wearing a denim shirt.
Gustavo França, a postdoctoral researcher in Yanai’s group and coauthor of the study, uses bioinformatics approaches to understand transcriptome complexity.
Gustavo França

“We see EMT early on, but it’s only one step along the way. It’s not the be-all and end-all. It seems that putting the cell into a more plastic state can resist the drug, but to achieve higher orders of resistance, there are other changes built on top of that,” explained Yanai. The resistant states showed increased fitness to the drug, and in the most fit states, the researchers observed metabolic rewiring.

The team wondered whether these adapted cell states were genetic. Using scRNA-seq and whole-exome sequencing, they observed copy number alterations associated with the states. The researchers found that during drug adaptation, chromatin reprogramming led to increased accessibility for stress response transcription factors and decreased accessibility for lineage markers, indicating dedifferentiation.

“This work provides important mechanistic insights, including the role of the EMT, into the evolution of therapeutic resistance in cancer cells,” said Beverly Emerson, a molecular biologist at Oregon Health and Science University, who was not involved in the study.

To study this process in vivo, the team generated two mouse models: one received an acute short-term treatment, while the other received prolonged long-term treatment. The acute regimen elicited a partial reprogramming while the long-term model revealed reprogramming that overlapped with the in vitro adapted resistant states. “[These findings] contribute much needed detail to our knowledge of evolutionary principles of survival at micro to macro scales—from cells to organisms to species,” remarked Emerson.

By mapping this dynamic resistance continuum, Yanai posits that researchers can exploit these defining features to develop drugs specific to particular resistance states. “The big, new frontier of how they adapt is not mutations, but rather that [cancer cells] somehow have this intrinsic ability to reprogram themselves,” said Yanai.

  1. Baym M, et al. Spatiotemporal microbial evolution on antibiotic landscapes. Science. 2016;353(6304):1147-1151.
  2. França GS, et al. Cellular adaptation to cancer therapy along a resistance continuum. Nature. 2024;631(8022):876-883.

Keywords

Meet the Author

  • Laura Tran, PhD

    Laura Tran, PhD

    Laura is an assistant editor for The Scientist. She earned her PhD in biomedical sciences from Rush University by studying how circadian rhythms and alcohol affect the gut.
Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide